» Articles » PMID: 17146434

Mouse Double Minute Antagonist Nutlin-3a Enhances Chemotherapy-induced Apoptosis in Cancer Cells with Mutant P53 by Activating E2F1

Overview
Journal Oncogene
Date 2006 Dec 6
PMID 17146434
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

MDM2 is a critical negative regulator of the p53 tumor suppressor protein. Recently, small-molecule antagonists of MDM2, the Nutlins, have been developed to inhibit the p53-MDM2 interaction and activate p53 signaling. However, half of human cancers have mutated p53 and they are resistant to Nutlin treatment. Here, we report that treatment of the p53-mutant malignant peripheral nerve sheath (MPNST) and p53-null HCT116 cells with cisplatin (Cis) and Nutlin-3a induced a degree of apoptosis that was significantly greater than either drug alone. Nutlin-3a also increased the cytotoxicity of both carboplatin and doxorubicin in a series of p53-mutant human tumor cell lines. In the human dedifferentiated liposarcoma cell line (LS141) and the p53 wild-type HCT116 cells, Nutlin-3a induced downregulation of E2F1 and this effect appeared to be proteasome dependent. In contrast, in MPNST and HCTp53-/- cells, Nutlin-3a inhibited the binding of E2F1 to MDM2 and induced transcriptional activation of free E2F1 in the presence of Cis-induced DNA damage. Downregulation of E2F1 by small interfering RNA significantly decreased the level of apoptosis induced by Cis and Nutlin-3a treatment. Moreover, expression of a dominant-negative form of E2F1 rescued cells from apoptosis, whereas cells overexpressing wild-type E2F1 showed an increase in cell death. This correlated with the induction of the proapoptotic proteins p73alpha and Noxa, which are both regulated by E2F1. These results indicate that antagonism of MDM2 by Nutlin-3a in cells with mutant p53 enhances chemosensitivity in an E2F1-dependent manner. Nutlin-3a therefore may provide a therapeutic benefit in tumors with mutant p53 provided it is combined with chemotherapy.

Citing Articles

Targeting MDM2 affects spastin protein levels and functions: implications for HSP treatment.

Sardina F, Polverino F, Valentini S, Carsetti C, Falvo E, Tisci G Cell Death Discov. 2025; 11(1):53.

PMID: 39920118 PMC: 11806007. DOI: 10.1038/s41420-025-02333-y.


Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens.

Alaseem A Saudi Pharm J. 2023; 31(10):101790.

PMID: 37818252 PMC: 10561124. DOI: 10.1016/j.jsps.2023.101790.


Targeting Cell Cycle Facilitates E1A-Independent Adenoviral Replication.

Ehrenfeld M, Segeth F, Mantwill K, Brockhaus C, Zhao Y, Ploner C J Virol. 2023; 97(6):e0037023.

PMID: 37219458 PMC: 10308897. DOI: 10.1128/jvi.00370-23.


Effects of wound dressing based on the combination of silver@curcumin nanoparticles and electrospun chitosan nanofibers on wound healing.

Liu C, Zhu Y, Lun X, Sheng H, Yan A Bioengineered. 2022; 13(2):4328-4339.

PMID: 35137655 PMC: 8973858. DOI: 10.1080/21655979.2022.2031415.


A Quantitative Systems Approach to Define Novel Effects of Tumour p53 Mutations on Binding Oncoprotein MDM2.

Fuentes M, Srivastava S, Gronenborn A, LaBaer J Int J Mol Sci. 2022; 23(1).

PMID: 35008477 PMC: 8744954. DOI: 10.3390/ijms23010053.